Hyperbaric Oxygen Therapy
Breathing pure oxygen in a pressurized chamber to enhance tissue oxygenation, promote healing, and stimulate stem cell mobilization.
Evidence Summary
Hyperbaric oxygen therapy (HBOT) has robust randomized-trial support across more than a dozen FDA-approved indications, and the evidence base for cognitive and cellular-aging applications strengthened over 2024–2025. In a prospective trial of 30 healthy aging adults (mean age ~68), 60 daily sessions at 2 ATA were associated with increased leukocyte telomere length (up to ~38% in B cells) and a reduction of senescent T-helper cells of roughly 37% (Hachmo et al., Aging, 2020). A 2024 systematic review and meta-analysis of 11 randomized controlled trials (847 patients) reported cognitive improvements in Alzheimer's disease and cognitive impairment (MMSE mean difference +3.08; ADAS-Cog −4.53) with adverse-event rates similar to control (Frontiers in Aging Neuroscience, 2024). A longitudinal follow-up of a randomized controlled trial in post-COVID condition found large improvements in neuropsychiatric symptoms, sleep and pain after 40 sessions at 2 ATA, largely sustained about one year after treatment (Efrati et al., Scientific Reports, 2024). These findings are promising but derive from small-to-moderate trials; HBOT for longevity and cognition remains investigational, is not a cure, and should be delivered only under qualified medical supervision after screening for contraindications.
Evidence Scale
Mechanism of Action
Increases dissolved oxygen in plasma by 10-15x, stimulating angiogenesis, reducing inflammation, mobilizing stem cells, and enhancing mitochondrial function through hypoxia-inducible factor (HIF) pathway modulation.
Who Is This For?
Non-healing wounds, post-radiation, TBI/concussion, anti-aging protocols. Baseline assessment recommended.
Protocol & Dosing
Dose
1.5-3.0 ATA pressure. Pure oxygen or enriched air depending on protocol.
Frequency
Daily to 3x/week
Duration
20-60 sessions typical
Protocol Summary
Sessions in pressurized chamber at 1.5-3.0 ATA for 60-90 minutes. Protocol varies by indication.
Latest Evidence
2024–2025: cognitive, cellular-aging & post-viral evidence
A 2024 systematic review and meta-analysis of 11 randomized controlled trials (847 patients) found hyperbaric oxygen therapy improved cognition in Alzheimer's disease and cognitive impairment — a mean MMSE gain of +3.08 points and an ADAS-Cog reduction of −4.53 — with adverse-event rates similar to control. A one-year longitudinal follow-up of a randomized controlled trial in post-COVID condition reported large improvements in neuropsychiatric symptoms (effect size 0.81), sleep and pain after 40 sessions at 2 ATA, with benefits largely sustained about 486 days after treatment. These build on an earlier prospective trial in healthy aging adults in which 60 sessions at 2 ATA were associated with longer immune-cell telomeres and fewer senescent T-cells.
These are small-to-moderate trials and, for longevity endpoints, largely early-stage. HBOT for cognition and healthy aging is investigational, is not a cure, and is delivered only under qualified medical supervision after screening for contraindications such as untreated pneumothorax. Educational information, not medical advice.
Prospective trial · n=30
Telomere length increase after HBOT
Source: Hachmo et al., Aging (Albany NY), 2020 — 30 healthy aging adults, 60 daily sessions at 2 ATA. Telomere length change from baseline measured after HBOT.
Related on Peak Human
HBOT at Peak Human
Physician-supervised hyperbaric oxygen protocols.
HBOT: Benefits & Latest Research
A plain-language review of the current HBOT evidence.
HBOT, Brain & Longevity
How HBOT is being studied for the brain and aging.
Therapeutic Plasma Exchange
Another regenerative therapy in the database.
Stem Cell Therapy
HBOT mobilizes stem cells; explore the related therapy.
Longevity Research Insider
Weekly review of new longevity research.
Key references: HBOT increases telomere length & reduces immunosenescence — Aging (2020) · HBOT for Alzheimer's disease: systematic review & meta-analysis — Front. Aging Neurosci. (2024) · Long-term outcomes of HBOT in post-COVID condition (RCT follow-up) — Scientific Reports (2024)
Interactions & Precautions
Contraindications
- Untreated pneumothorax
- Active malignancy (relative)
- Claustrophobia
- Certain medications
Potential Risks
- •Barotrauma
- •Oxygen toxicity at high pressures
- •Fire hazard in chamber
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Screen for contraindications. Soft chambers (1.3 ATA) offer milder alternative. Consider 40-session protocols for neurological applications.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation